Guidant is making its return to the market for defibrillators for patients with congestive heart failure. On Friday, the Indianapolis-based company won FDA approval for a fix for a defect which caused a small number of units to malfunction. The highly expensive devices, which cost around $30,000 each, were pulled from the market in June. Guidant shares rose in response to the news this morning, climbing 4 percent to $71.62 in morning trading.
- see this story [1] from TheStreet.com
PLUS: The New York Times this weekend published another account of a serious defibrillator incident. Story [2]
Links:
[1] http://www.thestreet.com/_googlen/stocks/biotech/10235795.html?cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA
[2] http://www.nytimes.com/2005/07/30/business/30guidant.html